ACR
$5M24mo
Acrux
Biotech · Dermatology
Topical drug delivery technology, LENZETTO hormone therapy
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.9M
Dec 2025 4C
Runway
24moSTABLE
Based on Dec 2025 4C
Market Cap
$5M
Burn Rate
$0.1M/qtr
Dec 2025 4C
Shares Outstanding
411M
Pipeline Assets
4
Latest Insight(1)
24 Feb 2026Half YearHalf Yearly Report and Accounts
Cash$0.9M·Burn$1.3M/q·OCF$-1.3M
3M Price
ACR.ASX$0.011-26.7% 3M
Low $0.011High $0.016
Pipeline Assets (4)
Dapsone 7.5% Gelacne vulgaris
NDA FiledEfinaconazole 10%toenail fungal infection
NDA FiledNitroglycerin 0.4% Ointmentchronic anal fissure
NDA FiledLenzettomenopausal hot flushes
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
3 approved drugs60 competitor trialsPhase 2+ · Non-ASX
Toenail Fungal Infection2 active trials
1 Ph31 Ph2
Chronic Anal Fissure2 active trials
2 Ph4
Approved
Menopausal Hot Flushes6 active trials
1 Ph41 Ph2/34 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)
Dapsone 7.5% Gel US launch revenue
UpcomingConfirmedremoveMed30 June 2026
Acyclovir Cream 5% FDA decision
UpcomingExpectedremoveMed31 Dec 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| Dapsone 7.5% Gel US launch revenue FDA approved Aug 2024, launched May 2025 via TruPharma. US market >US$37.4M annually | commercial milestone | Confirmed | removeMed |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Announcements(5)
payments
Quarterly 4CPSauto_awesome
Quarterly Activities/Appendix 4C Cash Flow Report28 Jan 2026
expand_more394KB